Costs and effects in therapy for acute coronary syndromes : The case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study : Use of GP IIb/IIIa inhibitors in coronary syndromes : State of the Art.
Cost-effectiveness analyses are routinely performed to determine whether the additional cost of a novel therapy is balanced by additional effectiveness.
The definitions of costs and effects involve a variety of assumptions, both in general economic terms and with regard to the specific medical setting under consideration.
Similarly, differing criteria for acceptability of cost-effectiveness estimates can be used to generate different conclusions regarding cost-effectiveness.
The issues and problems inherent in economic evaluation are discussed by an analysis of findings with the platelet glycoprotein llb/llla inhibitor abciximab in the EPIC (Evaluation of 7E3 for the Prevention of Ischemic Complications) study in high-risk patients undergoing percutaneous transluminal coronary angioplasty.
Mots-clés Pascal : Dilatation instrumentale, Sonde ballonnet, Artère coronaire, Abciximab, Inhibiteur, Glycoprotéine, Homme, Efficacité traitement, Coût, Economie santé, Prévention, Complication, Cardiopathie coronaire, Chimiothérapie, Traitement, Analyse coût efficacité, Traitement instrumental, Inhibiteur thromboagrégation, Appareil circulatoire pathologie, Glycoprotéine IIbIIIa
Mots-clés Pascal anglais : Instrumental dilatation, Cuffed tube, Coronary artery, Abciximab, Inhibitor, Glycoproteins, Human, Treatment efficiency, Costs, Health economy, Prevention, Complication, Coronary heart disease, Chemotherapy, Treatment, Cost efficiency analysis, Instrumentation therapy, Antiplatelet agent, Cardiovascular disease, Glycoprotein IIbIIIa
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0218385
Code Inist : 002B02G. Création : 11/09/1998.